Online and face-to-face programmes to suit your CPD needs, apply now for September 2018
Page URL: https://www.bionews.org.uk/page_92556

Genetic tests for autism, blindness and learning disabilities in clinics 'by 2011'

6 September 2010
Appeared in BioNews 574

Tests to diagnose learning disabilities, autism and blindness using a child's whole genome could become a reality in clinics by 2011, according to a leading Dutch academic...

Professor Joris Veltman, an Associate Professor in Genomic Disorders from the Radboud University Nijmegen Medical Centre is already trialling the tests at his clinic. Professor Veltman's tests use next generation DNA sequencing machines, which he has adapted for use in genetic testing. Current genetic tests look at mutations in a few genes. But next-generation DNA sequencers allow all human genes to be quickly decoded, by a method called exome sequencing.

This has been key to understanding the cause of rare diseases like Schinzel-Giedion syndrome, which has mental retardation as one of the clinical features. Using exome sequencing, Veltman's team recently showed that this condition is caused by different mutations in a single gene, called SETBP1.

'In many cases, exome sequencing allows us to make diagnoses simply and quickly', he says. 'It is changing dramatically the way we do genetic diagnoses'.

The new technique can also be used to advance scientific research into other genetic diseases. By sequencing all a child's coding DNA and comparing it to DNA from healthy parents, Professor Veltman's team can identify unique mutations in DNA that aren't present in a child's parents.

'We can identify de novo - those that aren't present in the parents - mutations or deletions and link these to disease even if they have never been seen in other patients before', he says. Some genetic disorders are caused by missing or 'deleted' sections of DNA.

Professor Veltman warns this technique will initially be expensive, but predicts it will become cheaper as it becomes more widespread.

'At the moment, this is still expensive. We now talk about exome sequencing costing a few €1000. For diagnostic use, we need each test to cost less than €1000', he says. 'But with upscaling, we see this as a possibility in the near future. In the Netherlands, it will be possible to start doing this diagnostically by 2011'.

Professor Joris Veltman's comments come in advance of a talk he will give about his work at 5pm on 6th September 2010 at the annual BSHG (British Society for Human Genetics) conference held at the University of Warwick from 6th to 8th September 2010.

SOURCES & REFERENCES
British Human Genetics Conference 2010 Programme
BSHG |  6 September 2010
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
8 October 2012 - by Dr Lucy Freem 
A streamlined method to find disease-causing single gene mutations has been developed to aid diagnosis of critically ill infants...
17 September 2012 - by James Brooks 
The genetics community needs to work far more collaboratively if it is to meet the challenges of the genomic era, warns Professor Sir John Burn, one of the UK's leading genetics experts...
26 March 2012 - by Dr Rosie Gilchrist 
Faulty genetic mechanisms particularly active in early life may lead to people developing autism, research suggests...
13 June 2011 - by Dr Lux Fatimathas 
American researchers have linked hundreds of spontaneous genetic mutations to the group of psychological syndromes called autism spectrum disorders (ASDs)...
25 October 2010 - by Professor Christopher Hood 
Direct-to-consumer personal genetic profiling services marketed as a way to predict people's future health risks may claim to be leading a new era of 'personalised healthcare', but the Nuffield Council on Bioethics believe these claims should be treated with caution...
27 September 2010 - by Dr Rachael Panizzo 
Researchers have successfully transplanted retinal cone cells into blind mice, making progress towards a stem cell treatment for a form of blindness that causes degeneration of the eye's retina...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.